Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

File(s)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.pdf (1.47 MB)

Published version

Show more

Author(s)

Schlackow, Iryna

Kent, Seamus

Herrington, William

Emberson, Jonathan

Haynes, Richard

more

Type

Journal Article

Date Issued

2019-07-01

Date Acceptance

2019-01-10

Citation

Kidney International, 2019, 96 (1), pp.170-179

URI

http://hdl.handle.net/10044/1/79695

URL

https://www.sciencedirect.com/science/article/pii/S0085253819301711?via%3Dihub

DOI

https://www.dx.doi.org/10.1016/j.kint.2019.01.028

ISSN

0085-2538

Publisher

Elsevier

Start Page

170

End Page

179

Journal / Book Title

Kidney International

Volume

96

Issue

1

Copyright Statement

© 2019, International Society of Nephrology. Published byElsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000472024100025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Subjects

Science & Technology

Life Sciences & Biomedicine

Urology & Nephrology

chronic kidney disease

cost-effectiveness

ezetimibe

health care costs

quality-adjusted life years

statin

SIMVASTATIN PLUS EZETIMIBE

RENAL PROTECTION

LDL CHOLESTEROL

CARDIOVASCULAR PREVENTION

RANDOMIZED-TRIAL

HEALTH

HEART

THERAPY

EUROQOL

SAFETY

Publication Status

Published

Date Publish Online

2019-03-12